Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus NORLUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus NORLUTIN.
HYDROXYPROGESTERONE CAPROATE vs NORLUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyprogesterone caproate is a synthetic progestin that acts as an agonist of the progesterone receptor. Its mechanism in preventing preterm birth is not fully understood but may involve suppression of uterine contractility, maintenance of cervical integrity, and modulation of the inflammatory response.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
250-500 mg intramuscularly once weekly. For recurrent preterm birth prevention: 250 mg intramuscularly weekly starting at 16-20 weeks gestation until 36 weeks.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
None Documented
None Documented
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Deslanoside
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyprogesterone caproate + Acetyldigitoxin
Terminal elimination half-life is approximately 7-8 days (range 5-14 days) due to slow release from the intramuscular depot, supporting weekly or biweekly dosing.
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Primarily renal as metabolites; approximately 50-60% of a dose is excreted in urine within 96 hours, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for approximately 30-40%.
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Category D/X
Category C
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Acetyldigitoxin."